## French National Agency for Medicines and Health Products Safety

CERTIFICATE NUMBER: 19MPP104HFR01

# CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

#### Part 1

Issued following an inspection in accordance with:

Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of France confirms the following:

The manufacturer: SANOFI CHIMIE

Site address: 45, chemin de Météline, BP 15, SISTERON, 04201, France

Is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 2019-11-22, it is considered that it complies with:

• The principles of GMP for active substances <sup>3</sup> referred to in Article 47 of Directive 2001/83/EC.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

Online EudraGMDP, Ref key: 74879 Issuance Date: 2020-02-13 Signatory: Confidential Page 1 of 1

<sup>&</sup>lt;sup>1</sup> The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

<sup>&</sup>lt;sup>2</sup> Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

<sup>&</sup>lt;sup>3</sup> These requirements fulfil the GMP recommendations of WHO.

#### Part 2

Manufacture of active substance. Names of substances subject to inspection:

CLOPIDOGREL HYDROGEN SULFATE(en)

DRONEDARONE HYDROCHLORIDE(en)

TICLOPIDINE HYDROCHLORIDE(en)

ALIMEMAZINE TARTRATE( en)

AMISULPRIDE( en)

CHLORPROMAZINE HYDROCHLORIDE(en)

PROMETHAZINE HYDROCHLORIDE(en)

TRIMIPRAMINE MALEATE( en)

ZOLPIDEM TARTRATE( en)

AVANAFIL( en)

SOTAGLIFLOZIN(en)

### 3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

Active Substance: CLOPIDOGREL HYDROGEN SULFATE

3.1	Manufacture of Active Substance by Chemical Synthesis	
	3.1.1 Manufacture of active substance intermediates	
	3.1.2 Manufacture of crude active substance	
	3.1.3 Salt formation / Purification steps :	
	Crystallization	
3.5	General Finishing Steps	
	3.5.1 Physical processing steps:	
	Filtration, drying	
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material	
	which is in direct contact with the substance)	
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging	
	material or container. This also includes any labelling of the material which could be used for	

3.6 **Quality Control Testing** 

3.6.1 Physical / Chemical testing

identification or traceability (lot numbering) of the active substance)

Active Substance : DRONEDARONE HYDROCHLORIDE		
3.1	Manufacture of Active Substance by Chemical Synthesis	
	3.1.1 Manufacture of active substance intermediates	
	3.1.2 Manufacture of crude active substance	
	3.1.3 Salt formation / Purification steps :	
	Crystallization	
3.5	General Finishing Steps	
	3.5.1 Physical processing steps :	
	Filtration, drying	
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material	
	which is in direct contact with the substance)	

Issuance Date: 2020-02-13

	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	material or container. This also includes any labelling of the material which could be used for
	identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Activ	re Substance : TICLOPIDINE HYDROCHLORIDE
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps : Crystallization
3.5	General Finishing Steps
	3.5.1 Physical processing steps :
	Filtration, drying
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
	which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Activ	re Substance : ALIMEMAZINE TARTRATE
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps :
2.5	Crystallization
3.5	General Finishing Steps
	3.5.1 Physical processing steps : Filtration, drying
	rittation, drying
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
	<ul> <li>3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)</li> <li>3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for</li> </ul>
	<ul> <li>3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)</li> <li>3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)</li> </ul>
3.6	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)  Quality Control Testing
3.6	<ul> <li>3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)</li> <li>3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)</li> </ul>
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)  Quality Control Testing
	<ul> <li>3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)</li> <li>3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)</li> <li>Quality Control Testing</li> <li>3.6.1 Physical / Chemical testing</li> </ul>
Activ	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)  Quality Control Testing  3.6.1 Physical / Chemical testing

Signatory: Confidential

	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps :
	Crystallization
3.5	General Finishing Steps
	3.5.1 Physical processing steps :
	Filtration, drying
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
	which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	material or container. This also includes any labelling of the material which could be used for
	identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Activ	e Substance : CHLORPROMAZINE HYDROCHLORIDE
3.1	Manufacture of Active Substance by Chemical Synthesis
001	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps:
	Crystallization
3.5	General Finishing Steps
	3.5.1 Physical processing steps:
	Filtration, drying
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
	which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	material or container. This also includes any labelling of the material which could be used for
	identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Activ	e Substance : PROMETHAZINE HYDROCHLORIDE
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps :
	Crystallization
3.5	General Finishing Steps
	3.5.1 Physical processing steps :
	Filtration, drying
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
	which is in direct contact with the substance)
1	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging

	identification or traceability (lot numbering) of the active substance)		
3.6	Quality Control Testing		
	3.6.1 Physical / Chemical testing		
	Dien Thysical Centure County		
Activ	e Substance : TRIMIPRAMINE MALEATE		
3.1	Manufacture of Active Substance by Chemical Synthesis		
	3.1.1 Manufacture of active substance intermediates		
	<ul><li>3.1.2 Manufacture of crude active substance</li><li>3.1.3 Salt formation / Purification steps :</li></ul>		
	Crystallization		
3.5	General Finishing Steps		
	3.5.1 Physical processing steps :		
	Filtration, drying		
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)		
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging		
	material or container. This also includes any labelling of the material which could be used for		
	identification or traceability (lot numbering) of the active substance)		
3.6	Quality Control Testing		
	3.6.1 Physical / Chemical testing		
Active Substance : ZOLPIDEM TARTRATE			
3.1	Manufacture of Active Substance by Chemical Synthesis		
	3.1.1 Manufacture of active substance intermediates		
	<ul><li>3.1.2 Manufacture of crude active substance</li><li>3.1.3 Salt formation / Purification steps :</li></ul>		
	Crystallization		
3.5	General Finishing Steps		
	3.5.1 Physical processing steps :		
	Filtration, drying		
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)		
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging		
	material or container. This also includes any labelling of the material which could be used for		
2.6	identification or traceability (lot numbering) of the active substance)		
3.6	Quality Control Testing		
	3.6.1 Physical / Chemical testing		
Activ	e Substance : AVANAFIL		
3.1	Manufacture of Active Substance by Chemical Synthesis		
	3.1.1 Manufacture of active substance intermediates		
	3.1.2 Manufacture of crude active substance		
	3.1.3 Salt formation / Purification steps :		

Signatory: Confidential

	Crystallization	
3.5	General Finishing Steps	
	3.5.1 Physical processing steps :	
	Filtration, drying	
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material	
	which is in direct contact with the substance)	
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging	
	material or container. This also includes any labelling of the material which could be used for	
2.6	identification or traceability (lot numbering) of the active substance)	
3.6	Quality Control Testing	
	3.6.1 Physical / Chemical testing	
Active Substance : SOTAGLIFLOZIN		
3.1	Manufacture of Active Substance by Chemical Synthesis	
	3.1.1 Manufacture of active substance intermediates	
	3.1.2 Manufacture of crude active substance	
	3.1.3 Salt formation / Purification steps :	
	crystallization	
3.5	General Finishing Steps	
	3.5.1 Physical processing steps :	
	Filtration and drying	
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material	
	which is in direct contact with the substance)	
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging	
	material or container. This also includes any labelling of the material which could be used for	
2.6	identification or traceability (lot numbering) of the active substance)	
3.6	Quality Control Testing	
	3.6.1 Physical / Chemical testing	

Clarifying remarks (for public users)

Signatory: Mrs Linda Gallais, head of starting materials inspection department --- The ANSM does not issue hard copies of good practices certificates

Online EudraGMDP, Ref key: 74879 Issuance Date: 2020-02-13 Signatory: Confidential Page 6 of



Name and signature of the authorised person of the Competent Authority of France

-----

Confidential

French National Agency for Medicines and Health Products Safety

Tel: Confidential
Fax: Confidential